ERBB2 and breast cancer: 64Cu-DOTA trastuzumab PET/CT has also been studied in 6 breast cancer patients (3 primary and 3 metastatic HER2(+) disease) with at least 1 lesion visible by PET/CT on all patients imaged [44].